KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug ... 100% higher than those from the ...

The mean baseline blood glucose levels (expressed in mg/dL) were 88.2&PlusMinus ... tirzepatide-induced insulin levels were as much as approximately 100% higher than those from the Zepbound® ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide ... (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

from 100 mg/g to 5,000 mg/g. They were on maximally tolerated renin-angiotensin system inhibitors. Drug discontinuation was slightly higher for semaglutide (12.6%) than placebo (11.3%), mostly ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction in their body weight. This marks a significant achievement in the ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Zepbound (tirzepatide ... and 15 milligrams (mg) resulted in significant and sustained weight loss. The study, which had support from the drug’s manufacturer, found that tirzepatide resulted ...